Skip header and navigation

Refine By

3 records – page 1 of 1.

Effects of trans- and n-3 unsaturated fatty acids on cardiovascular risk markers in healthy males. An 8 weeks dietary intervention study.

https://arctichealth.org/en/permalink/ahliterature53319
Source
Eur J Clin Nutr. 2004 Jul;58(7):1062-70
Publication Type
Article
Date
Jul-2004
Author
J. Dyerberg
D C Eskesen
P W Andersen
A. Astrup
B. Buemann
J H Christensen
P. Clausen
B F Rasmussen
E B Schmidt
T. Tholstrup
E. Toft
S. Toubro
S. Stender
Author Affiliation
Department of Human Nutrition, The Royal Veterinary and Agricultural University, Frederiksberg, Denmark. jdcon@post4.tele.dk
Source
Eur J Clin Nutr. 2004 Jul;58(7):1062-70
Date
Jul-2004
Language
English
Publication Type
Article
Keywords
Adult
Biological Markers - blood
Cardiovascular Diseases - blood - prevention & control
Cholesterol - blood
Double-Blind Method
Fatty Acids, Omega-3 - administration & dosage - pharmacology
Heart Rate - drug effects - physiology
Humans
Lipoproteins - blood
Lipoproteins, HDL Cholesterol - blood
Lipoproteins, LDL Cholesterol - blood
Male
Middle Aged
Research Support, Non-U.S. Gov't
Risk factors
Trans Fatty Acids - administration & dosage - pharmacology
Triglycerides - blood
Abstract
BACKGROUND: Studies of long-term intake of industrially produced trans fatty acids (TFA) and n-3 polyunsaturated fatty acids (PUFA) suggest opposite effects on cardiovascular disease risk. Common mechanisms of action are probable. OBJECTIVE: To examine the effects on cardiovascular risk markers of dietary enrichment with TFA or n-3 PUFA. DESIGN: Randomized, double-blind, parallel intervention trial. SETTING: Department of Human Nutrition, The Royal Veterinary and Agricultural University. SUBJECTS: In all, 87 healthy males included, 79 completed. INTERVENTION: Subjects were randomly assigned to 8 weeks of a daily intake of 33 g of experimental fats from either partially hydrogenated soy oil containing 20 g of TFA, 12 g of fish oil with approximately 4 g of n-3 PUFA and 21 g of control fat, or 33 g of control fat. The experimental fats were incorporated into bakery products. Plasma lipids, blood pressure, heart rate variability (HRV), arterial dilatory capacity, compliance, and distensibility were recorded before and after intervention and at follow-up 12 weeks after the intervention. RESULTS: High-density lipoprotein cholesterol (HDL-C) decreased in the TFA group and triglycerides and mean arterial blood pressure decreased in the n-3 PUFA group compared to the control group. HRV, arterial dilatory capacity, compliance, and distensibility were unchanged. CONCLUSION: The results indicate that the association between coronary heart disease risk and intake of TFA and n-3 PUFA relates only modestly to changes in traditional risk markers. SPONSORSHIP: Danish Medical Research Council (Grant no. 22-01-0390), Center of Advanced Food Research (Copenhagen, Denmark) (Grant no. KVL-R-2001-107), the Danish Heart Association (Grant no. 99-2-3-45-22748), Novozymes (Bagsvaerd, Denmark), Aarhus Olie (Aarhus, Denmark), and from private sources. The experimental fats were provided by Pronova Biocare (Aalesund, Norway) and Aarhus Olie (Aarhus, Denmark).
PubMed ID
15220949 View in PubMed
Less detail

N-3 fatty acids and cardiac function after myocardial infarction in Denmark.

https://arctichealth.org/en/permalink/ahliterature53849
Source
Int J Circumpolar Health. 2001 Aug;60(3):360-5
Publication Type
Article
Date
Aug-2001
Author
H A Skou
E. Toft
J H Christensen
J B Hansen
J. Dyerberg
E B Schmidt
Author Affiliation
Department of Medicine, Hjørring Hospital, Denmark. helleskou@hotmail.com
Source
Int J Circumpolar Health. 2001 Aug;60(3):360-5
Date
Aug-2001
Language
English
Publication Type
Article
Keywords
Aged
Comparative Study
Dietary Supplements
Double-Blind Method
Drug Administration Schedule
Echocardiography
Fatty Acids, Omega-3 - therapeutic use
Female
Follow-Up Studies
Humans
Male
Middle Aged
Myocardial Infarction - complications - diagnosis - drug therapy
Probability
Reference Values
Statistics, nonparametric
Treatment Outcome
Ventricular Dysfunction, Left - diagnosis - drug therapy - etiology
Abstract
In order to evaluate the effect of marine n-3 polyunsaturated fatty acids (n-3 PUFA) on systolic left ventricular function, we investigated the effect of daily supplementation with 5.2 g n-3 PUFA for 12 weeks in 55 patients with a recent myocardial infarction in a double blind placebo-controlled design. Left ventricular function was assessed by transthoracal echo-cardiography and plasma concentration of proANP and N-terminal proANP. No effect of n-3 PUFA could be demonstrated on these indices of left ventricular function.
PubMed ID
11590875 View in PubMed
Less detail

Plasma levels of marine n-3 fatty acids and cardiovascular risk markers in renal transplant recipients.

https://arctichealth.org/en/permalink/ahliterature289343
Source
Eur J Clin Nutr. 2016 07; 70(7):824-30
Publication Type
Journal Article
Research Support, Non-U.S. Gov't
Date
07-2016
Author
I A Eide
D O Dahle
M Svensson
A Hartmann
A Åsberg
K S Bjerve
J H Christensen
E B Schmidt
M E Lauritsen
K Lund
T Jenssen
Author Affiliation
Section of Nephrology, Department Transplant Medicine, Oslo University Hospital, Oslo, Norway.
Source
Eur J Clin Nutr. 2016 07; 70(7):824-30
Date
07-2016
Language
English
Publication Type
Journal Article
Research Support, Non-U.S. Gov't
Keywords
Adult
Blood Glucose - metabolism
Blood Pressure - drug effects
Cardiovascular Diseases - blood - etiology - prevention & control
Cholesterol, HDL - blood
Cohort Studies
Cross-Sectional Studies
Diet
Dietary Fats - blood - pharmacology
Fatty Acids, Omega-3 - blood - pharmacology
Female
Fish Oils - blood
Heart Rate - drug effects
Humans
Kidney - surgery
Kidney Transplantation - adverse effects
Male
Middle Aged
Norway
Phospholipids - metabolism
Pulse Wave Analysis
Risk factors
Seafood
Triglycerides - blood
Abstract
Cardiovascular (CV) disease is the leading cause of death after renal transplantation. Marine n-3 polyunsaturated fatty acids (PUFAs) exert potential cardio-protective metabolic effects and might reduce CV morbidity and mortality in renal transplant recipients (RTRs).
In this cross-sectional study of 1990 Norwegian RTRs, transplanted between 1999 and 2011, associations between plasma phospholipid marine n-3 PUFA levels and various CV risk markers at 10 weeks after transplant were evaluated.
Higher plasma marine n-3 PUFA levels were associated with lower resting heart rate (rHR), lower fasting plasma glucose (fPG) levels, lower plasma triglyceride levels and higher plasma high-density lipoprotein (HDL) cholesterol levels. Plasma levels of eicosapentaenoic acid, but not docosahexaenoic acid, showed a positive association with plasma HDL cholesterol levels. Plasma marine n-3 PUFA levels were not associated with plasma low-density lipoprotein cholesterol levels, pulse wave velocity or systolic and diastolic blood pressure. A negative association between plasma marine n-3 PUFA levels and CV mortality was weakened by additional adjustment for plasma triglyceride levels and rHR. The ratio of n-6 to n-3 PUFAs showed similar associations with CV risk markers as absolute plasma marine n-3 PUFA levels.
This is the first study in RTRs showing that marine n-3 PUFAs are negatively associated with rHR and fPG in addition to beneficial effects on plasma HDL cholesterol and triglyceride levels. Especially, effects on autonomic nervous function and triglyceride metabolism might contribute to explain the lower CV mortality risk with higher plasma marine n-3 PUFA levels previously shown in this cohort.
Notes
Cites: N Engl J Med. 2011 Jun 23;364(25):2439-50 PMID 21696310
Cites: Am J Clin Nutr. 1992 Jun;55(6):1126-34 PMID 1350705
Cites: Nephron. 1998 Sep;80(1):57-60 PMID 9730704
Cites: Am J Kidney Dis. 1987 Jan;9(1):60-5 PMID 3544824
Cites: Am J Clin Nutr. 2009 Sep;90(3):613-20 PMID 19625683
Cites: BMJ. 1996 Mar 16;312(7032):677-8 PMID 8597736
Cites: Br J Nutr. 2013 Mar 28;109(6):1123-34 PMID 22846205
Cites: BMC Public Health. 2014 Feb 20;14:186 PMID 24555673
Cites: Clin J Am Soc Nephrol. 2013 Nov;8(11):1968-78 PMID 23929933
Cites: Transplantation. 2007 Apr 15;83(7):831-8 PMID 17460552
Cites: Am J Kidney Dis. 1998 Nov;32(5 Suppl 3):S112-9 PMID 9820470
Cites: J Clin Lipidol. 2012 Jan-Feb;6(1):5-18 PMID 22264569
Cites: J Am Soc Nephrol. 2005 Aug;16(8):2462-70 PMID 15958723
Cites: Am J Cardiol. 2006 Nov 15;98(10):1393-5 PMID 17134636
Cites: Atherosclerosis. 2006 Nov;189(1):19-30 PMID 16530201
Cites: J Hypertens. 2002 Aug;20(8):1493-9 PMID 12172309
Cites: Am J Clin Nutr. 2011 Oct;94(4):973-80 PMID 21865334
Cites: Pediatr Transplant. 2012 Dec;16(8):835-9 PMID 22835217
Cites: Am J Transplant. 2010 Feb;10(2):338-53 PMID 20415903
Cites: Diabetes Care. 1992 Mar;15(3):430-41 PMID 1559410
Cites: Br J Nutr. 2012 Jun;107 Suppl 2:S214-27 PMID 22591895
Cites: Am J Clin Nutr. 2011 Aug;94(2):543-51 PMID 21677058
Cites: Clin J Am Soc Nephrol. 2015 Jul 7;10(7):1246-56 PMID 26063768
Cites: Heart. 2014 Apr;100(7):569-73 PMID 24352736
Cites: Am J Clin Nutr. 2011 Sep;94(3):884-91 PMID 21775559
Cites: Am J Clin Nutr. 2012 Jun;95(6):1445-53 PMID 22572642
Cites: J Ren Nutr. 2012 Nov;22(6):525-32 PMID 22698988
Cites: Ann Intern Med. 2011 Aug 2;155(3):160-70 PMID 21810709
Cites: Arch Intern Med. 2012 May 14;172(9):686-94 PMID 22493407
Cites: Am J Clin Nutr. 2011 Feb;93(2):446-54 PMID 21147858
Cites: Atherosclerosis. 2008 Mar;197(1):12-24 PMID 18160071
Cites: Lancet. 1999 Aug 7;354(9177):447-55 PMID 10465168
Cites: Circulation. 2006 Jan 17;113(2):195-202 PMID 16401768
Cites: Kidney Int. 2013 Jun;83(6):1130-5 PMID 23389417
Cites: Lancet. 2011 Oct 15;378(9800):1419-27 PMID 22000138
Cites: N Engl J Med. 2012 Jul 26;367(4):309-18 PMID 22686415
Cites: Am J Clin Nutr. 2015 Jul;102(1):49-57 PMID 26016867
Cites: Am J Clin Nutr. 2006 Jun;83(6 Suppl):1505S-1519S PMID 16841861
Cites: Blood Coagul Fibrinolysis. 1995 Feb;6(1):17-22 PMID 7795149
Cites: Transplantation. 2015 Aug;99(8):1730-7 PMID 25757216
Cites: Lancet. 2007 Mar 31;369(9567):1090-8 PMID 17398308
Cites: Evid Rep Technol Assess (Summ). 2005 Feb;(115):1-11 PMID 15810864
Cites: N Engl J Med. 1990 Mar 22;322(12):795-801 PMID 2137901
Cites: Metabolism. 1997 Dec;46(12 Suppl 1):40-3 PMID 9439558
Cites: Nutr Metab Cardiovasc Dis. 2014 Dec;24(12):1310-6 PMID 25063539
Cites: Nutr Metab Cardiovasc Dis. 2007 Oct;17 (8):572-80 PMID 17127043
Cites: Diabetes Care. 2014;37(1):189-96 PMID 24026545
Cites: Ann Intern Med. 2006 Aug 15;145(4):247-54 PMID 16908915
Cites: Eur J Clin Nutr. 2015 Mar;69(3):322-8 PMID 25248358
Cites: Nephrol Dial Transplant. 2014 Jan;29(1):128-36 PMID 23229929
PubMed ID
26931669 View in PubMed
Less detail